Type 1 diabetes

Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes has grown substantially, particularly with regard to disease prediction and heterogeneity, pancreatic pathology, and epidemiology. Technological improvements in insulin pumps and continuous glucose monitors he...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) Jg. 383; H. 9911; S. 69 - 82
Hauptverfasser:	Atkinson, Mark A, Eisenbarth, George S, Michels, Aaron W
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Kidlington Elsevier Ltd 04.01.2014 Elsevier Elsevier Limited
Schlagworte:	Age Autoimmune diseases Biological and medical sciences Cardiovascular disease Diabetes Diabetes Mellitus, Type 1 - complications Diabetes Mellitus, Type 1 - diagnosis Diabetes Mellitus, Type 1 - epidemiology Diabetes Mellitus, Type 1 - therapy Diabetes. Impaired glucose tolerance Diabetic neuropathy Diabetic retinopathy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Epidemiology Etiopathogenesis. Screening. Investigations. Target tissue resistance General aspects Glucose Heterogeneity Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - therapeutic use Insulin Insulin - administration & dosage Insulin - therapeutic use Internal Medicine Islets of Langerhans - pathology Medical sciences Mortality Pancreas, Artificial Pathogenesis Pathology Peptides Studies Teenagers Europe Finland Endocrinopathy Medicine Immunopathology Autoimmune disease Type 1 diabetes
ISSN:	0140-6736, 1474-547X, 1474-547X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Over the past decade, knowledge of the pathogenesis and natural history of type 1 diabetes has grown substantially, particularly with regard to disease prediction and heterogeneity, pancreatic pathology, and epidemiology. Technological improvements in insulin pumps and continuous glucose monitors help patients with type 1 diabetes manage the challenge of lifelong insulin administration. Agents that show promise for averting debilitating disease-associated complications have also been identified. However, despite broad organisational, intellectual, and fiscal investments, no means for preventing or curing type 1 diabetes exists, and, globally, the quality of diabetes management remains uneven. This Seminar discusses current progress in epidemiology, pathology, diagnosis, and treatment of type 1 diabetes, and prospects for an improved future for individuals with this disease.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-1
ISSN:	0140-6736 1474-547X 1474-547X
DOI:	10.1016/S0140-6736(13)60591-7